Skip to main content
. 2020 Aug 20;11(8):663. doi: 10.1038/s41419-020-02907-x

Fig. 2. EpCAM is expressed in cisplatin resistant cells and EpCAM inhibition sensitizes HNSCC cells to cisplatin and inhibits HNSCC cell proliferation.

Fig. 2

a Expression of EpCAM mRNA in HNSCC patients’ cisplatin resistant and sensitive tumor cells. b Dose-response and cell viability of HNSCC patient tumor cells (top panel), SCC15 (middle panel), and FaDu (bottom panel) cells. Cell viability of siEpCAM and scrambled siRNA transfected cells were monitored following exposures of cells to different concentrations of cisplatin. c EC50 of cisplatin in parental, si-scrambled, and siEpCAM transfected patient tumor cells (top panel), SCC15 (middle panel), and FaDu (bottom panel) cells. The EC50 differences between si-scramble and siEpCAM cells were compared. d Relative EpCAM mRNA expression in HNSCC patient tumor cells (top panel), SCC15 (middle panel), and FaDu (bottom panel) cells following transfection of cells by si-scrambled and siEpCAM. p-values were calculated using Student’s t test. e Cell proliferation was determined following transfection of cells by si-scrambled and siEpCAM. Si-scrambled and siEpCAM cell growth was compared on day 5. ns denote not significant, *p < 0.05, **p < 0.01, ***p < 0.001.